Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has given tentative approval to Teva Pharmaceutical Industries' application to market a generic equivalent of Procter & Gamble's Actonel tablets indicated for treatment and prevention of postmenopausal induced osteoporosis, and Paget's disease.
Subscribe to our email newsletter
However, final approval is subject to the resolution of pending patent litigation after Procter & Gamble sued Teva last year over patent infringement of the drug.
If Teva is granted a firm go-ahead from the FDA, it can begin to participate in a market for the drug thought to be worth approximately $942 million.
A generic drug product is one that is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics and intended use. New drug applications for generic drugs are termed “abbreviated” because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness.